Instrument Inactif

Communiqués DIAL BIORFD Nasdaq Stockholm

Actions

DIABIO BTA

SE0019173832

Recherche biotechnologique et médicale

Communiqués

11/12	Diagonal Bio has been declared in bankruptcy	AQ
11/12	Diagonal Bio intends to submit a formal application for bankruptcy	AQ
01/12	Nomination Committee appointed for Diagonal Bio	AQ
04/11	Untersteiner Racing signs agreement for a pilot test	AQ
31/10/25	Diagonal Bio publishes interim report for the third quarter of 2025	AQ
13/10/25	Diagonal Bio launches new website to reflect commercial focus on the Animal Health segment	AQ
03/10/25	Diagonal Bio initiates collaboration with SVA on evaluation of coronavirus in horses	AQ
23/09/25	Diagonal Bio expands horse testing panel to detect Equine Herpesvirus type 2	AQ
18/09/25	Diagonal Bio receives order from Stall Courant	AQ
22/08/25	Diagonal Bio publishes interim report for the second quarter of 2025	AQ
20/08/25	Diagonal Bio AB receives patent approval in Japan	AQ
07/07/25	Diagonal Bio AB files patent application for Novel Computational Method that significantly improves LAMP primer design	AQ
25/06/25	The Board of Directors of Diagonal Bio carries out a directed issue to underwriters in connection with exercise of warrants of series TO 2	AQ
19/06/25	Diagonal Bio receives SEK 3.6 million through exercise of warrants of series TO 2	AQ
17/06/25	Update regarding large shareholder’s exercise of warrants of series TO 2	AQ
17/06/25	Diagonal Bio expands equine panel with addition of strangles	AQ
16/06/25	Large shareholder exercises warrants of series TO 2	AQ
13/06/25	Last day of trading in Diagonal Bio’s warrants of series TO 2 is 16 June 2025	AQ
11/06/25	Diagonal Bio shares progress update on LAMPlify® commercial pilots	AQ
09/06/25	Svea Bank AB invests SEK 0.5 million in Diagonal Bio AB through the exercise of warrants of series TO 2	AQ
04/06/25	The exercise period for Diagonal Bio’s warrants of series TO 2 starts today	AQ
20/05/25	Bulletin from the Annual General Meeting on 20 May 2025 in Diagonal Bio AB	AQ
16/05/25	Diagonal Bio secures 100 percent of forthcoming warrant exercise through pre-subscription and underwriting commitments	AQ
14/05/25	Diagonal Bio publishes interim report for the first quarter of 2025	AQ
05/05/25	Diagonal Bio accelerates its commercialisation efforts with the appointment of Anders Wallseth as Senior Commercial Advisor	AQ